Ivonescimab is an innovative bispecific antibody that has attracted global attention for its encouraging results in the treatment of non-small cell lung cancer (NSCLC). By combining two therapeutic mechanisms into a single medicine, it represents a new generation of cancer immunotherapy. For patients in India who are exploring advanced treatment options, it is important to understand where the therapy is currently approved, its regulatory status and the possible pathways through which it may become accessible.
What Is Ivonescimab and How Does It Work?
Ivonescimab, also known as AK112 or SMT112, is the world’s first humanized bispecific antibody designed to simultaneously target programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). These two biological pathways play distinct but complementary roles in cancer progression. PD-1 suppresses the body’s immune response against tumors, while VEGF promotes the formation of new blood vessels that supply oxygen and nutrients to cancer cells.
Ivonescimab is designed to strengthen the immune system’s ability to recognize and destroy cancer cells while also limiting the tumor’s blood supply by inhibiting both pathways at the same time. This dual-targeting approach has demonstrated promising clinical outcomes, particularly in patients with advanced NSCLC, and continues to be evaluated across multiple cancer types.
Ivonescimab Global Approval and Regulatory Status
The Ivonescimab availability currently differs considerably across countries.
China became the first country to approve Ivonescimab in May 2024, where it is marketed for specific patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC. The therapy was subsequently added to China’s National Reimbursement Drug List (NRDL) from January 1, 2025, significantly improving patient access within the country.
In the United States, Ivonescimab remains an investigational therapy. A Biologics License Application (BLA) was accepted by the U.S. Food and Drug Administration in early 2026, with a regulatory decision expected on November 14, 2026. Until a final decision is reached, the medicine is not commercially available in the U.S.
Across Europe and most other regions, Ivonescimab continues to be evaluated through clinical studies and has not yet received routine marketing authorization.
Ivonescimab Access Options for Patients in India
At present, Ivonescimab has not been approved by the Central Drugs Standard Control Organisation (CDSCO) for commercial use in India. Consequently, it is not routinely available through hospitals or pharmacies. However, depending on individual circumstances and regulatory requirements, patients may have several potential avenues to explore.
One possible pathway is participation in international clinical trials. Clinical studies remain the primary mechanism through which investigational medicines are made available before commercial approval. Several multinational Phase 3 studies are evaluating Ivonescimab, including the HARMONi-3 trial. While this study includes research centers in countries such as the United States, China, France, Germany, Japan and Spain, there are currently no active Indian trial sites. Patients interested in clinical research should discuss ongoing trial opportunities with their treating oncologist, who can help determine whether enrollment at an international study center may be appropriate.
Another route involves obtaining treatment in countries where Ivonescimab has already received regulatory approval. Since the medicine is commercially available in China, eligible patients may choose to receive treatment there under the supervision of licensed oncology specialists. Such treatment requires careful planning, including medical evaluation, travel arrangements, treatment scheduling and continued follow-up with both the treating physicians abroad and the patient’s healthcare team in India.
For patients who are unable to participate in clinical trials or travel overseas, future regulatory approval in India remains an important long-term pathway. Indian approval generally follows a detailed review of clinical evidence and manufacturing quality. Decisions made by major regulatory agencies, along with the availability of global Phase 3 data, often support subsequent submissions in other countries. Depending on regulatory requirements, additional bridging studies or local clinical data may also be requested before routine commercialization in India.
What Is the Future of Ivonescimab Access?
The progress of Ivonescimab through late-stage clinical development has generated considerable interest among oncologists because of its novel mechanism and encouraging efficacy data. If regulatory approvals continue in major international markets, access opportunities for patients in countries such as India may gradually expand over the coming years.
For patients who have been prescribed Ivonescimab, 24/7QualityMeds supports prescription-based sourcing and applicable international import requirements, helping patients and families coordinate access to specialty medicines through the appropriate pathway. Support is available for patients worldwide, including those seeking to buy Ivonescimab in Mumbai, Delhi, Chennai and Kolkata.
To request Ivonescimab, contact 24/7QualityMeds at +91 9967979080 for assistance with prescription requirements, international sourcing and the applicable access process.
Until then, treatment decisions should always be made in consultation with a qualified medical oncologist, who can assess whether currently approved therapies, participation in clinical trials or other access pathways are appropriate for an individual patient’s condition.
Ivonescimab Safety and Treatment Considerations
Like all advanced cancer therapies, Ivonescimab should only be administered under specialist medical supervision. Clinical studies have demonstrated encouraging efficacy, but treatment is also associated with adverse effects that require careful monitoring throughout therapy.
Among the most commonly reported side effects are hypertension (high blood pressure) and proteinuria (protein in the urine), findings that are consistent with medicines targeting the VEGF pathway. These effects are generally manageable with regular monitoring and appropriate medical intervention, but they require ongoing assessment during treatment.
Rare but potentially serious immune-related complications have also been reported. One such event is immune-mediated thrombotic thrombocytopenic purpura (iTTP), an uncommon condition that can affect blood clotting and multiple organ systems. Although rare, such reactions highlight the importance of prompt recognition and specialist management.
Patients considering Ivonescimab should have detailed discussions with their oncology team regarding its potential benefits, possible risks, eligibility criteria and how it compares with other approved treatment options currently available for their specific type and stage of cancer.
